Published online Jul 15, 2021. doi: 10.4239/wjd.v12.i7.1116
Peer-review started: March 2, 2021
First decision: April 6, 2021
Revised: April 11, 2021
Accepted: May 20, 2021
Article in press: May 20, 2021
Published online: July 15, 2021
Processing time: 132 Days and 1.6 Hours
Retinal neovascularization is caused by the progression of ischemic retinal diseases, including diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, and retinal vein occlusion. Complications of retinal neovascularization can severely impair vision or lead to permanent blindness.
To explore the upstream molecules of vascular endothelial growth factor or rate-limiting steps of angiogenesis, and to reveal new approaches to the treatment of diabetic retinal.
The research on the role of piRNAs (p-Element-induced wimpy testis-interacting RNAs) in retinal neovascularization disease is expected to provide theoretical support for the clinical treatment of diabetic retina.
A diabetic retinopathy model was established. The differentially expressed piRNA was screened by high-throughput sequencing, and the differentially expressed piRNA was selected according to the sequencing results, and verified by polymerase chain reaction.
A total of 79 piRNAs were differentially expressed in experimental group, of which 43 were upregulated and 36 were down-regulated.
piRNAs were differentially expressed in DR model. Differentially expressed piRNAs is involved in the formation of retinal neovascularization. Differentially expressed piRNAs can regulate retinal development and retinal angiopathy through a variety of signaling pathways.
Drugs targeting piRNAs may be novel candidates for the treatment of diabetic retinopathy.